This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary objective of this review is to determine the effect of pentoxifylline on the cumulative incidence of BPD (supplemental oxygen at 36 weeks' PMA), death prior to 36 weeks' PMA and BPD or death prior to 36 weeks' PMA in preterm neonates < 32 weeks' GA or < 1500 g birth weight.
Secondary objectives include potential benefits of pentoxifylline in terms of mortality, respiratory morbidity prior to hospital discharge, complications of preterm birth and adverse events.
Subgroup analysis is planned considering whether GA at birth (extremely preterm neonates < 28 weeks' GA, very preterm neonates 29 to 31 weeks' GA) or the route of drug delivery (intravenous versus nebulised pentoxifylline) influences outcomes of the systematic review.